Press Releases

Biocon Biologics  /  Press Releases

Tata Memorial Hospital Team Presents Biocon’s Nimotuzumab Study Results at ASCO Annual Meeting 2018

  • Posted by: Biocon Biologics

Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of Ogivri™, the first biosimilar for Herceptin®, approved by US FDA

  • Posted by: Biocon Biologics

Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr

  • Posted by: Biocon Biologics

Kiran Mazumdar-Shaw #1 Business Captain in ‘The Medicine Maker 2018 Power List’

  • Posted by: Biocon Biologics

Mylan and Biocon Receive Approvals from the European Commission and TGA, Australia for Semglee™ Biosimilar Insulin Glargine

  • Posted by: Biocon Biologics

Mylan and Biocon Receive Positive CHMP Opinion for Semglee™, Biosimilar Insulin Glargine

  • Posted by: Biocon Biologics

Biocon Q3FY18 Revenue at Rs 1092 Crore; EBITDA at Rs 256 Crore; Net Profit at Rs 92 Crore

  • Posted by: Biocon Biologics

Biocon Announces Exclusive Global Collaboration with Sandoz on Next-Generation Biosimilars

  • Posted by: Biocon Biologics

Biocon and Mylan’s Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through Their Partner Libbs

  • Posted by: Biocon Biologics

U.S. FDA Approves Mylan and Biocon´s OgivriTM the First Biosimilar for Trastuzumab, for the Treatment of HER2­Positive Breast and Gastric Cancers

  • Posted by: Biocon Biologics
Share